Facts for Prelims (FFP)
Source: TH
Context: The Medicines Patent Pool (MPP) has signed sub-licence agreements with some Indian companies, as well as an Indonesian firm to produce generic versions of the cancer drug Nilotinib.
- Nilotinib, used for treating chronic myeloid leukaemia, is currently marketed by Novartis under the brand name Tasigna.
About Medicines Patent Pool:
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of, life-saving medicines for low- and middle-income countries.
Significance of the move:
- This move is expected to make cancer treatment more affordable and accessible to patients in low- and middle-income countries, providing a much-needed treatment option for those diagnosed with chronic myeloid leukaemia.
